Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
2Activity
0 of .
Results for:
No results containing your search query
P. 1
Claus Fuglsang - Novozymes - Stanford - Jan 30 2012

Claus Fuglsang - Novozymes - Stanford - Jan 30 2012

Ratings: (0)|Views: 107|Likes:
Published by Burton Lee

More info:

Published by: Burton Lee on Feb 01, 2012
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

12/08/2013

pdf

text

original

 
January 30
th
2012
Stanford Engineering,
European Entrepreneurship
& Innovation
Claus Crone FuglsangManaging DirectorNovozymes Inc.
 
2
A growing globalpopulation puts pressureon our natural resources.With bioinnovation in theform of, for example,industrial enzymes andmicroorganisms, industriescan rethink their processesand products, and producemore with less.
 
Business consists of two segments:Enzyme Business and BioBusiness
2011 sales: USD ~ 2 billion
2011 EBIT margin: 22.3%
More than 700 products used in 130countries in over 40 different industries
~ 7,000 granted and pending patents
+ 5,800 employees
Two share classes; A and B shares
A share capital and 11% of B shares
(25.5% of O/S; 70.1% of votes) held byNovo A/S, the management company of the Novo Nordisk Foundation
Novozymes
 The World Leader in Bioinnovation
* A+B shares January, 2012
Founded 1941Listed 2000Ticker NZYM BExchange CopenhagenMarket Cap*~ 10 Billion USDEnzyme BusinessBioBusiness
HouseholdCareFood & BeveragesBioenergyFeed & other Tech.Micro-organismsBiopharma3

Activity (2)

You've already reviewed this. Edit your review.
1 thousand reads
1 hundred reads

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->